SEC Filings

SEC Filings

Filing date	Description	Form	View
May 25, 2018	Specialized Disclosure Report	SD	View HTML 0001104659-18-035999.pdf 0001104659-18-035999.rtf 0001104659-18-035999.xls
May 21, 2018	Simplified registration form	S-3	View HTML 0001104659-18-034839.pdf 0001104659-18-034839.rtf 0001104659-18-034839.xls
May 21, 2018	Amendment to a previously filed 4	4/A	View HTML 0001214659-18-003935.pdf 0001214659-18-003935.rtf 0001214659-18-003935.xls
May 18, 2018	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-18-034465.pdf 0001104659-18-034465.rtf 0001104659-18-034465.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003871.pdf 0001214659-18-003871.rtf 0001214659-18-003871.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003872.pdf 0001214659-18-003872.rtf 0001214659-18-003872.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003873.pdf 0001214659-18-003873.rtf 0001214659-18-003873.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003874.pdf 0001214659-18-003874.rtf 0001214659-18-003874.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003875.pdf 0001214659-18-003875.rtf 0001214659-18-003875.xls
May 17, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-003876.pdf 0001214659-18-003876.rtf 0001214659-18-003876.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE